Role of mTOR signaling pathway for the growth and proliferation of uterine leiomyoma
Project/Area Number |
23592393
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Chiba University |
Principal Investigator |
ISHIKAWA Hiroshi 千葉大学, 医学(系)研究科(研究院), 助教 (70553973)
|
Co-Investigator(Kenkyū-buntansha) |
SHOZU Makio 千葉大学, 大学院医学研究院, 教授 (30226302)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 子宮筋腫 / mTOR / 動物モデル / xenograft / 免疫不全マウス / hypoxia / HIF1 / 重症免疫不全マウス / Hypoxia / メトホルミン / 移植モデル |
Research Abstract |
We investigated the role of mammalian target of rapamycin (mTOR) signaling pathway for the growth and proliferation of uterine leimyoma; however, we did not find any overexpression of protein levels as well as mRNA levels of mTOR signaling pathway-related genes in uterine leiomyoma compared with those in myometrial tissues. Next, we established a novel in vivo xenograft model for uterine leiomyoma, and evaluated its characters. The non-obese diabetic/severe combined immunodeficient murine xenograft model has shown a sex-steroid dependent growth of xenograft beneath the kidney capsule, a positive expression for both estrogen and progesterone receptors, and a similar representative gene expression compared with original leiomyoma tissue. In this model, we use only non-genetic manupilated primary cultured leiomyoma cells; therefore, we believe this model is a good tool for the research and the development of new therapies for uterine leiomyoma.
|
Report
(4 results)
Research Products
(18 results)